Clinical Trial Detail

NCT ID NCT02730312
Title PH 1 Study to Evaluate Safety and Tolerability of XmAb14045 in Patients With CD123-expressing Hematologic Malignancies
Recruitment Recruiting
Gender both
Phase Phase I
Variant Requirements No
Sponsors Xencor, Inc.
Indications

chronic myeloid leukemia

acute myeloid leukemia

B-cell acute lymphoblastic leukemia

Therapies

XmAb14045

Age Groups: adult senior

No variant requirements are available.